Email: Password:
| Forgot Password

We're Sorry, This Program has Expired

Our CME programs expire after 1 year to ensure current and practical information

Cartoon of a doctor upset the program is expired

A free online accredited CPD program for healthcare professionals

A New Horizon In Atopic Dermatitis: Topical Therapy Latest Evidence & Potential Of A New Topical Treatment

1.00 Canadian Council On Continuing Education In Pharmacy (CCCEP) CEU(s) / 1.00 Ordre des pharmaciens du Québec (OPQ) CEU(s)

Program available online until: July 17, 2019

This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP)
for 1.00 CEU(s).

This continuing education activity has been accredited by l'Ordre des Pharmaciens du Quebec, which will grant 1.00 CEU(s) to pharmacists who have completed it successfully.

Discovering A New Topical Treatment Horizon In Mild To Moderate Atopic Dermatitis


Atopic dermatitis (AD) is a chronic and recurring skin condition, with symptoms that can be life-altering. The development of an emerging treatment offers a new option for AD (or eczema) sufferers, adding to the armamentarium for treating AD. Targeted topical therapy can expand the choice of therapy based on the growing understanding of the mechanisms underlying AD. Pharmacists play a key role as members of the healthcare team, to advise AD patients and support them while also working collaboratively with physicians.

This program discusses the role of the pharmacist and translating new evidence into treatment of mild to moderate atopic dermatitis (AD).

Planning Committee

  • Miriam Weinstein, BSc, BScN, MD, FRCPC (Paediatrics), FRCPC (Dermatology).
  • Michael Boivin, B.Pharm., CDE, CTE, CTH.
  • Jessie Haggai, B.Pharm, CDE.

Learning Objectives

After completion of the program, participants will be able to:

  1. Identify the pathophysiology and prevalence of atopic dermatitis (AD), the role of current topical therapy and a newly available topical treatment for mild to moderate atopic dermatitis (AD).
  2. Implement an AD treatment strategy that recognizes the effects of AD on patients’ quality of life and includes targeted topical treatment and realistic SMART goals (e.g. Specific, Measurable, Attainable, Relevant, Time-based).
  3. Identify the importance of reducing flares or recurrence and reinforce the ongoing daily protection of the skin barrier to optimize AD long-term management.
  4. Reinforce the importance of the appropriate application and use of topical treatment as part of an adherence strategy.
  5. Improve counselling and patient education by encouraging the pharmacist’s role in monitoring prescribed topical AD therapy.

Find out more from our Expert: Dr. Miriam Weinstein, BSc, BScN, MD, FRCPC (Paediatrics), FRCPC (Dermatology)

  • What specific information do you provide when counselling patients about the proper use of topical treatment for atopic dermatitis (AD)?
  • What concerns do patients and parents have about the use of topical corticosteroids (TCS)?
  • What are the key points to communicate to patients or caregivers about the differences between the current topical treatments for AD?
  • What do you tell a patient or caregivers who raise concerns about using a topical corticosteroid or topical calcineurin inhibitor due to a fear of adverse effects?
  • What do you consider a treatment failure and describe your step-wise approach to the treatment of mild to moderate AD?
  • Where do you see a new nonsteroidal treatment such as crisaborole fitting among the current classes of topical treatments?

mdBriefCase is the practical choice to earn your CPD Credits

Icon of multiple pages

20+ therapeutic areas

100+ programs each year.

Icon of multiple pages

Quality, accredited content

Developed by leading specialists and peer-reviewed by experts at respected institutions.

Icon of multiple pages

Online convenience

Save time and money.

Join 45,000+ of your colleagues

Create your free account today